You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復鋭醫療科技(01696.HK):天津星魅生物科技獲A輪投資1.09億元
格隆匯 12-22 21:32

格隆匯12月22日丨復鋭醫療科技(01696.HK)發佈公告,於2020年12月22日,公司的附屬公司復鋭醫療天津(作為原股東及A輪投資方)與復星健康基金(蘇州)及復星健康基金(天津)(二者的普通合夥人均為復星醫藥的附屬公司)以及目標公司天津星魅生物科技有限公司訂立A輪投資協議,內容有關向目標公司累計出資人民幣1.09億元,其中復鋭醫療天津同意出資人民幣1000萬元。

根據A輪投資協議,於A輪投資完成後,倘目標公司擬發行額外股份以籌集資金,且復星健康基金(蘇州)及復星健康基金(天津)擬參與此類融資,則復鋭醫療天津亦將認購目標公司的額外股份,並按於A輪投資完成後其於目標公司的持股比例額外出資,但復鋭醫療天津的最高出資額不超過人民幣1036.7萬元。因此,復鋭醫療天津已向目標公司出資以及已同意根據A輪投資協議出資的總金額為人民幣2148.7萬元。

天津星魅根據中國法律於2020年九月成立,其業務範圍包括在中國開發、分銷和銷售生物技術產品等。於2020年九月,天津星魅與Raziel訂立許可及供應協議,據此,Raziel向天津星魅授出許可,許可天津星魅在中國(包括香港、澳門及台灣地區)開發及商業化RZL012。RZL012用於美容和多種肥胖疾病的治療。

公司認為,天津星魅投資將使公司能夠通過天津星魅與Raziel合作,提高集團的醫療美容技術、專業知識及設計能力;及探索交叉銷售機會。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account